Cardiovascular Protection

The efficacy and safety of MICARDIS^® has been evaluated in one of the most comprehensive cardiovascular (CV) trial programmes for an angiotensin II receptor blocker (ARB).

The ONTARGET^® Trial Programme^1-4 is the largest clinical study programme to date to investigate the use of an ARB (MICARDIS^®) and an angiotensin-converting enzyme (ACE) inhibitor (ramipril) alone or in combination for preventing CV morbidity and mortality.   In addition, five out of the ten trials included in the PROTECTION^® Trial Programme⁵ evaluated the use of MICARDIS^® in the treatment of hypertension.

The ONTARGET^® Trial Programme – The Facts

The landmark clinical trial programme in cardiovascular protection comprising the parallel ONTARGET^® and TRANSCEND^® studies

Together, these studies have enrolled 31,456 patients at high CV risk from all inhabited continents and different ethnicities

ONTARGET^® includes the broadest cross-section of patients with high-risk cardiovascular disorders ever studied in this clinical setting

ONTARGET^® aims to investigate whether the ARB MICARDIS^®, combined with the ramipril, reduces CV mortality and morbidity in patients above the age of 55 years at high CV risk even further than ramipril alone. The study will also compare the cardioprotective effects of MICARDIS^® and ramipril monotherapies

In the parallel TRANSCEND^® study, the effects of MICARDIS^® versus placebo are assessed in patients who are intolerant of ACE inhibitors but are at high risk of a CV event

If MICARDIS^® demonstrates cardioprotective effects in both studies, the patient group that will benefit from treatment will be very broad

A further seven sub-studies will evaluate the additional functional and morphological effects of MICARDIS^® and ramipril therapy, identify possible blood markers for CV risk and estimate the economics of treatment^1-3

The PROTECTION Trial Programme – The Facts

Ten clinical trials, that included more than 6,500 patients from 32 countries

Investigated the effects of MICARDIS^® in preventing target-organ damage and treating hypertension, especially in high-risk and difficult-to-treat patient populations

Included patients with risk factors such as hypertension, diabetes and early end-organ diseases

Data from the VIVALDI,⁶  AMADEO,⁷ TRENDY,⁸ DETAIL,^9,10 INNOVATION¹¹ studies add to the existing information on the effect of ARBs and other antihypertensive drugs in patients at high risk for end-stage renal disease

PRISMA I & II,^12,13 SMOOTH,¹⁴ ATHOS,¹⁵ ARBs-FDC¹⁶ provide new evidence on the benefits of effective 24-hour blood pressure control for protection against the morning blood pressure surge, particularly in high-risk populations